Miles Congreve

Miles Congreve has extensive experience in the pharmaceutical industry, with a focus on drug discovery and chemistry. Miles began their career at GlaxoSmithKline in 1993, leading a team that developed innovative chemistry technology. In 2001, they joined Astex Therapeutics as the Director of Chemistry, where they established and managed a chemistry team specializing in Fragment Based Drug Discovery and structure-based drug design. In 2008, they moved to Sosei Heptares as the Chief Scientific Officer, overseeing the development and implementation of structure-based drug design approaches for GPCR targets. Miles held various positions at Sosei Heptares, including VP Chemistry, SVP Drug Discovery, and finally CSO. In 2022, Congreve joined Isomorphic Labs as the Chief Scientific Officer.

Miles Congreve obtained a Bachelor of Science (BSc) in Biological Chemistry from the University of Leicester in 1990. Miles then pursued a PhD in Chemistry at the University of Cambridge from 1990 to 1993.